PGENNasdaqPharmaceutical PreparationsFiscal year ends December 31
PRECIGEN, INC.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 4, 2026
$6.66+0.28 (+4.31%)
Close on Oct 19, 2026
- Market cap
- $2.76B
- P/E (TTM)
- –
- Dividend yield
- –
Share price
+$2.66 (+66.50%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
PRECIGEN, INC. grew revenue 146.7% to $9.68M over fiscal 2025. Free cash flow was -$115.22M.
Revenue
$9.68M
+146.7% vs. a year earlier
Operating income
-$110.51M
FY2025
Free cash flow
-$115.22M
TTM Q2 2026
EPS, diluted
-$1.10
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Jun 30, 2026
Valuation
- Market cap
- $2.76B
- P/E ratio
- –
- Price to sales
- 284.51
- Price to book
- 63.23
- Dividend yield
- –
- Free cash flow yield
- -4.18%
Fundamentals
- Revenue
- $9.68M
- Net income
- -$157.71M
- EPS, diluted
- -$1.10
- Free cash flow
- -$115.22M
- Book value per share
- $0.11
- Diluted shares
- 414M
Fifteen years at a glance
Fiscal years 2011 to 2025 and trailing twelve months, USD
Revenue
–
Gross profit
–
Operating income
–
Net income
-$157.71M
EPS, diluted
-$1.10
Free cash flow
-$115.22M
Reported periodTrailing twelve months